Clinical Evaluation of Photobiomodulated Hyaluronic Acid Therapy for Interdental Papillary Loss: Minimal Invasive Blind Split Mouth Technique

This study explores a novel, minimally invasive therapeutic approach to treating interdental papillary loss (IDP)-a condition with both functional and esthetic consequences, particularly in the maxillary anterior region. While surgical techniques for papilla regeneration have been investigated for decades, success has been limited due to anatomical challenges such as restricted blood supply and the small volume of tissue involved. Additionally, many of these procedures are invasive, complex, and do not guarantee long-term stability.

The proposed study evaluates the synergistic effect of photobiomodulation therapy (PBMT), formerly known as low-level laser therapy (LLLT), when combined with injectable hyaluronic acid (HA) dermal filler. PBMT is known to enhance microcirculation, stimulate fibroblast activity, and promote angiogenesis, all of which may contribute to improved tissue regeneration. HA, on the other hand, supports extracellular matrix remodeling, tissue hydration, and wound healing. While HA has shown some promise when used alone for papilla reconstruction, recurrence of papillary loss has been reported within 6-12 months post-treatment.

This clinical trial employs a split-mouth, randomized controlled design to compare two interventions within the same patient-HA filler alone versus HA combined with PBMT. By minimizing inter-patient variability, this design enhances internal validity and provides a more reliable comparison of treatment efficacy.

Throughout a 12-month follow-up period, the study will assess changes in papillary height, width, and overall tissue volume using standardized clinical measurements and digital imaging analysis. Additionally, the PBMT group will receive laser therapy at each follow-up session to evaluate its ongoing regenerative contribution.

This study aims to introduce a patient-friendly, conservative alternative to surgical procedures, with the potential to become a predictable and reproducible technique in the esthetic zone. If successful, it may offer a paradigm shift in managing one of the most challenging soft tissue defects in periodontal and esthetic dentistry.

Inclusion criteria

• Adults aged 20 to 40 years
• Presence of at least two non-adjacent interdental papilla defects (Class I, Norland & Tarnow classification) in the maxillary anterior region
• Healthy periodontal status, with:
• Probing depth ≤ 3 mm
• No gingival recession
• No tooth mobility (Score 0)
• No interdental bone loss on radiographs
• Non-smokers
• No previous orthodontic treatment
• Free from gingival or dental surface alterations (e.g., abfraction, irregularities, or overcontouring)
• Systemically healthy (no systemic diseases or conditions affecting healing or immune function)
• Willing and able to comply with study procedures and follow-up visits
• Provided written informed consent after explanation of study procedures

Exclusion criteria

• Candidates will be excluded if they meet any of the following:
• Systemic diseases or medications known to affect soft tissue healing (e.g., diabetes, immunosuppressants)
• Pregnancy or lactation
• History of periodontal surgery in the study area
• Known allergy or hypersensitivity to hyaluronic acid or local anesthetics
• Current use of anti-inflammatory drugs, anticoagulants, or antibiotics that could affect healing
• Poor oral hygiene or non-compliance during pre-treatment phase
• Participation in another clinical trial within the last 3 months